Plasma levels of apolipoprotein E and risk of dementia in the general population

Annals of Neurology

Volumn 77, Issue 2, 2015, Pages 301-311

  Rasmussen, Katrine L ^a,b   Tybjærg Hansen, Anne ^a,b,c,d   Nordestgaard, Børge G ^b,c,d   Frikke Schmidt, Ruth ^a,b,d  

^a Rigshospitalet   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

ADULT; ALLELE; ALZHEIMER DISEASE; ARTICLE; DEMENTIA; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; DENMARK; FOLLOW UP; HEALTH SURVEY; MIDDLE AGED; PROCEDURES;

AGED; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84922782657     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24326     Document Type: Article

References (45)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-344.
2. World Health Organization and Alzheimer's Disease International. Dementia: a public health priority. Geneva, Switzerland: WHO Press, 2012.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
4. Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011;10:241-252.
5. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009;41:1094-1099.
6. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088-1093.
7. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010;303:1832-1840.
8. Naj AC, Jun G, Beecham GW, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011;43:436-441.
9. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011;43:429-435.
10. Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013;12:207-216.
11. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res 2009;50(suppl):S183-S188.
12. Cramer PE, Cirrito JR, Wesson DW, et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;335:1503-1506.
13. th ed. New York, NY: McGraw-Hill, 2001:2835-2862.
14. Utermann G, Hees M, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977;269:604-607.
15. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, et al. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 2000;41:1812-1822.
16. Siest G, Bertrand P, Qin B, et al. Apolipoprotein E polymorphism and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. ApoEurope group. Clin Chem Lab Med 2000;38:721-730.
17. Cruchaga C, Kauwe JS, Nowotny P, et al. Cerebrospinal fluid apoE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet 2012;21:4558-4571.
18. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008;299:2524-2532.
19. Zacho J, Tybjaerg-Hansen A, Jensen JS, et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
20. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009;301:2331-2339.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Frikke-Schmidt R, Sing CF, Nordestgaard BG, Tybjaerg-Hansen A. Gender- and age-specific contributions of additional DNA sequence variation in the 5′ regulatory region of the APOE gene to prediction of measures of lipid metabolism. Hum Genet 2004;115:331-345.
23. Barret JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
24. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999;150:341-353.
25. Vijayaraghavan S, Maetzler W, Reinmold M, et al. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia. Alzheimers Dement 2014;10:530.e1-540.e1.
26. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
27. Hu WT, Holtzman DM, Fagan AM, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 2012;79:897-905.
28. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol 2012;69:1310-1317.
29. Lista S, Faltraco F, Prvulovic D, Hampel H. Blood and plasma-based proteomic biomarker research in Alzheimer's disease. Prog Neurobiol 2013;101-102:1-17.
30. Martel CL, Mackic JB, Matsubara E, et al. Isoform-specific effects of apolipoprotein E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 1997;69:1995-2004.
31. Linton MF, Gish R, Hubl ST, et al. Phenotypes of apolipoprotein B and apolipoprotein E after liver transplantation. J Clin Invest 1991;88:270-281.
32. Wahrle SE, Holtzman DM. Differential metabolism of apoE isoforms in plasma and CSF. Exp Neurol 2003;183:4-6.
33. Deane R, Sagare A, Hamm K, et al. apoE isoform-specific disruption of amyloid beta clearance from mouse brain. J Clin Invest 2008;118:4002-4013.
34. Bekris LM, Galloway NM, Montine TJ, et al. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet Part B 2010;153B:409-417.
35. Yu CE, Devlin B, Galloway N, et al. ADLAPH: A molecular haplotyping method based on allele-discriminating long-range PCR. Genomics 2004;84:600-612.
36. Yu CE, Seltman H, Peskind ER, el al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 2007;89:655-665.
37. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-264.
38. Bales KR, Verina T, Cummins DJ, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 1999;96:15233-15238.
39. DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 2004;41:193-202.
40. Bell RD, Winkler EA, Singh I, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012;485:512-516.
41. Daneman R, Zhou L, Kebede AA, Barres BA. Pericytes are required for blood-brain barrier integrity during embryogenesis. Nature 2010;468:562-566.
42. Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature 2010;468:557-561.
43. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011;12:723-738.
44. Simon R, Girod M, Fonbonne C, et al. Total ApoE and ApoE4 isoform assay in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides. Mol Cell Proteomics 2012;11:1389-1403.
45. Ulrich JD, Burchett JM, Restivo JL, et al. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener 2013;8:13.